ASSESSMENT OF THE NEUROLOGICAL DEFICIT OF PATIENTS WITH HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE 1A AFTER REHABILITATION USING COMMONLY ACCEPTED SCALES AND QUESTIONNAIRES
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i4.13233Keywords:
hereditary motor sensory neuropathy, rehabilitationAbstract
SUMMARY. There are currently no effective treatments for patients with hereditary motor and sensory neuropathy (HMSN) type 1A. Such patients are prescribed comprehensive rehabilitation programs, as well as symptomatic drug therapy.
The aim – to assess the impact of complex rehabilitation on the dynamics of the disease based on a follow-up analysis of the clinical characteristics of patients with HMSN type 1A.
Material and Methods. The study involved 63 patients with HMSN type 1A aged 36 to 60 years, who were divided into the main and control groups. The main group consisted of patients, who, since the onset of the disease, underwent annual comprehensive rehabilitation programs, as well as symptomatic drug therapy. The control group included patients who did not receive comprehensive rehabilitation programs. To objectify the clinical symptoms, an assessment of the neurological deficit in patients was carried out using scales and questionnaires: NIS, NDS, ODSS, MRC-SS, Barthel index, “Functional categories of walking” test, and the questionnaire "Short Form Medical Outcomes Study (SF-36)".
Results. The severity of neurological deficit in patients with HMSN type 1A in the control group was higher compared to patients in the main group. In patients of the main group, predominantly moderate severity of the disease was observed in 71.4 % of cases; mild – in 28.6 % of cases. In patients of the control group, an average severity of the disease was observed in 46.4 % of cases; severe – in 53.6 %; mild disease was not observed. In patients of the main group, the average values of quality of life indicators on all scales of the SF-36 questionnaire were higher than in such control groups.
Conclusions. Regular comprehensive rehabilitation programs significantly reduce the rate of disease progression in patients with HMSN type 1A, contribute to the stabilization of the pathological process, and improve the quality of life of patients.
References
Morena, J., Gupta, A., & Hoyle, J.C. (2019). Charcot-Marie-Tooth: From Molecules to Therapy. International Journal of Molecular Sciences, 20(14), 3419. DOI: 10.3390/ijms20143419.
Mills, T., Marks, E., Reynolds, T., & Cieza, A. (2017). Rehabilitation: Essential along the Continuum of Care. In D. T. Jamison (Eds.). Disease Control Priorities: Improving Health and Reducing Poverty. (3rd ed.). The International Bank for Reconstruction and Development. The World Bank. DOI: 10.1596/978-1-4648-0527-1_ch15.
Chitapure, T., Jethwani, D., Zubair Ahmed, S., & Panigrahy, C. (2021). Impact of Customized and Sustained Physiotherapy in Charcot-Marie-Tooth Disease. Cureus, 13(8), e17201. DOI: 10.7759/cureus.17201.
Shy, M.E., Blake, J., Krajewski, K., Fuerst, D.R., Laura, M., Hahn, A.F., Li, J., Lewis, R.A., & Reilly, M. (2005). Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology, 64(7), 1209-1214. DOI: 10.1212/01.WNL.0000156517.00615.A3.
Souza, C.C., Vallim, J., Neves, E., Nunes, P. S., Costa, I., Barreto, L., Garcez, C.A., & Araujo, A. (2022). Effectiveness of a specific physical therapy program for Charcot-Marie-Tooth on sleep quality, pain perception, and nocturnal cramps: a pilot study. Sleep Science (Sao Paulo, Brazil), 15(3), 326-333. DOI: 10.5935/1984-0063.20220058.
El Mhandi, L., Millet, G.Y., Calmels, P., Richard, A., Oullion, R., Gautheron, V., & Féasson, L. (2008). Benefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth disease. Muscle & Nerve, 37(5), 601-610. DOI: 10.1002/mus.20959.
Kenis-Coskun, O., & Matthews, D.J. (2016). Rehabilitation issues in Charcot-Marie-Tooth disease. Journal of Pediatric Rehabilitation Medicine, 9(1), 31-34. DOI: 10.3233/PRM-160359.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
